keyword
MENU ▼
Read by QxMD icon Read
search

Her2 breast cancer

keyword
https://www.readbyqxmd.com/read/29236315/lnc-rna-snhg20-participated-in-proliferation-invasion-and-migration-of-breast-cancer-cells-via-mir-495
#1
Yan-Xing Guan, Zhan-Min Zhang, Xue-Zhong Chen, Qing Zhang, Shao-Zheng Liu, Yong-Lu Zhang
OBJECTIVE: To explore the mechanism of lnc SNHG20 in the regulation of proliferation, invasion and migration of breast cancer cells. MATERIALS AND METHODS: mRNA levels of SNHG20, miR-495 and HER2 were detected by qRT-PCR. Protein level of HER2 was measured by Western blot. Cell proliferation, invasion and migration were detected by CCK-8 assay, Boyden chamber assay and Transwell assay. The combination between SNHG20 and miR-495 was confirmed by RNA pull down assay...
December 13, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29234254/prognostic-significance-of-focal-adhesion-kinase-in-node-negative-breast-cancer
#2
Katrin Almstedt, Isabel Sicking, Marco J Battista, Shangou Huangfu, Anne-Sophie Heimes, Veronika Weyer-Elberich, Annette Hasenburg, Marcus Schmidt
Background: Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays an important role as a mediator of cell migration, invasion, proliferation and survival. Conflicting results for the prognostic role of FAK in breast cancer (BC) prompted us to determine its impact. Methods: Patients with node-negative BC entered this retrospective study. FAK expression was determined by immunohistochemistry (n = 335). The prognostic impact of FAK was examined with Cox regression analyses and Kaplan-Meier estimation in the whole cohort as well as in different molecular subtypes...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234252/targeted-intraoperative-radiotherapy-tumour-bed-boost-during-breast-conserving-surgery-after-neoadjuvant-chemotherapy-a-subgroup-analysis-of-hormone-receptor-positive-her2-negative-breast-cancer
#3
Hans-Christian Kolberg, György Lövey, Leyla Akpolat-Basci, Miltiades Stephanou, Peter Fasching, Michael Untch, Oliver Hoffmann, Max Bulsara, Jayant Vaidya, Cornelia Liedtke
Introduction: In a previous study our group showed a beneficial effect of targeted intraoperative radiotherapy (TARGIT-IORT) as an intraoperative boost on overall survival after neoadjuvant chemotherapy (NACT) compared to an external boost (EBRT). In this study we present the results of a detailed subgroup analysis of the hormone receptor (HR)-positive HER2-negative patients. Methods: In this cohort study involving 46 patients with HR-positive HER2-negative breast cancer after NACT, we compared the outcomes of 21 patients who received an IORT boost to those of 25 patients treated with an EBRT boost...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234249/mechanisms-of-resistance-to-cdk4-6-inhibitors-in-breast-cancer-and-potential-biomarkers-of-response
#4
REVIEW
Cristina Guarducci, Martina Bonechi, Giulia Boccalini, Matteo Benelli, Emanuela Risi, Angelo Di Leo, Luca Malorni, Ilenia Migliaccio
Randomized clinical trials demonstrated that CDK4/6 inhibitors are highly effective in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer in combination with endocrine therapy. The use of CDK4/6 inhibitors in clinics is becoming common for patients with HR+/HER2- metastatic breast cancer and will certainly increase in the near future. However, patients might show de novo or acquired resistance to these drugs. Molecular alterations have been suggested as determinants for de novo resistance to CDK4/6 inhibitors, but have never been validated in a clinical setting...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234247/pi3k-mtor-inhibitors-in-the-treatment-of-luminal-breast-cancer-why-when-and-to-whom
#5
REVIEW
Francesco Schettini, Giuseppe Buono, Meghana V Trivedi, Sabino De Placido, Grazia Arpino, Mario Giuliano
Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in luminal breast cancer (BC). Despite the efficacy of endocrine agents, many patients with luminal BC do not respond to endocrine therapy and many others develop endocrine resistance over time, due to the activation of escape pathways such as the PI3K/AKT/mTOR signaling. Several clinical trials have demonstrated the efficacy of mTOR and PI3K inhibitors in overcoming endocrine resistance in hormone receptor-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic BC (MBC) patients...
October 2017: Breast Care
https://www.readbyqxmd.com/read/29234246/is-there-still-a-role-for-first-line-single-agent-endocrine-therapy-in-hr-and-her2-advanced-breast-cancer
#6
EDITORIAL
Luca Malorni, Laura Biganzoli
No abstract text is available yet for this article.
October 2017: Breast Care
https://www.readbyqxmd.com/read/29233824/role-for-immune-therapy-in-advanced-breast-cancer
#7
(no author information available yet)
In a phase Ib/II trial, adding the PD-1 inhibitor pembrolizumab to trastuzumab showed clinical benefit in patients with advanced HER2-positive breast cancer who had developed resistance to trastuzumab. The study also identified tumor-infiltrating lymphocyte levels as a potential biomarker of response to treatment.
December 12, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29233559/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast-cancer-a-pooled-analysis-of-3771-patients-treated-with-neoadjuvant-therapy
#8
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang D Schmitt, Jens-Uwe Blohmer, Thomas Karn, Berit M Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiss, Arndt Hartmann, Aurelia Noske, Peter A Fasching, Christian Jackisch, Marion van Mackelenbergh, Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, but their role in luminal breast cancer and the effect of TILs on prognosis in all subtypes is less clear. Here, we assessed the relevance of TILs for chemotherapy response and prognosis in patients with TNBC, HER2-positive breast cancer, and luminal-HER2-negative breast cancer. METHODS: Patients with primary breast cancer who were treated with neoadjuvant combination chemotherapy were included from six randomised trials done by the German Breast Cancer Group...
December 7, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29233126/positive-prognostic-value-of-her2-her3-co-expression-and-p-mtor-in-gastric-cancer-patients
#9
Guo-Dong Cao, Ke Chen, Bo Chen, Mao-Ming Xiong
BACKGROUND: The HER2-HER3 heterodimer significantly decreases survival in breast cancer patients. However, the prognostic value of HER2-HER3 overexpression remains unknown in gastric cancer (GC). METHODS: The expression levels of HER2, HER3, Akt, p-Akt, mTOR and p-mTOR were examined in specimens from 120 GC patients by immunohistochemistry and quantitative reverse transcription-PCR. The associations of HER proteins, PI3K/Akt/mTOR pathway-related proteins, clinicopathological features of GC, and overall survival (OS) were assessed...
December 12, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29232309/a-bispecific-antibody-based-on-pertuzumab-fab-has-potent-antitumor-activity
#10
Wentong Deng, Jiayu Liu, Haitao Pan, Li Li, Changhua Zhou, Xiaojuan Wang, Rui Shu, Bin Dong, Donglin Cao, Qing Li, Zhong Wang
Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed and activated in metastatic breast cancers. Monoclonal antibodies targeting Her2, such as trastuzumab and pertuzumab, have become important targeted therapies for patients with HER2-positive breast cancer. Both trastuzumab and pertuzumab can reduce Her2 positive tumor burden by inhibiting Her2 signaling and inducing ADCC activities (antibody dependent cell-mediated cytotoxicity). In this study, we have generated a bispecific antibody, Her2(Per)-S-Fab, by linking the pertuzumab Fab to an anti-CD16 single domain antibody...
January 2018: Journal of Immunotherapy
https://www.readbyqxmd.com/read/29231164/lapatinib-plus-capecitabine-in-patients-with-her2-positive-metastatic-breast-cancer-a%C3%A2-systematic-review%C3%A2
#11
Rebecca Madden, Sam Kosari, Gregory M Peterson, Nasser Bagheri, Jackson Thomas
OBJECTIVE: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 - 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with trastuzumab, the first-line treatment, there is a need for effective second-line therapies in treating HER2-positive breast cancer. In this context, there has been increasing interest in the combination of lapatinib plus capecitabine. The aim of this systematic review was to assess the efficacy of lapatinib plus capecitabine for HER2-positive breast cancer after progression with trastuzumab therapy, in comparison with capecitabine monotherapy and other agents such as vinorelbine and trastuzumab emtansine...
December 12, 2017: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29230390/her2-overexpression-in-retinoblastoma-a-potential-therapeutic-target
#12
David Cordeiro Sousa, Pablo Zoroquiain, Maria Eugenia Orellana, Ana Beatriz Dias, Evangelina Esposito, Miguel N Burnier
Background: Retinoblastoma (RB) is the most common primary intraocular malignancy. Current therapies are associated with high morbidity in the short- and long-term. Human epidermal growth factor receptor 2 (HER2) is a transmembrane protein detected in 15-30% of breast cancers, but it has also been described in other malignancies. Recently, it has been claimed that a truncated version of this protein is expressed in RB, responsive to directed therapies in vitro. We scored HER2 overexpression in RB tissue samples and discussed its potential clinical utility...
September 2017: Ocular Oncology and Pathology
https://www.readbyqxmd.com/read/29230121/leptomeningeal-disease-and-the-evolving-role-of-molecular-targeted-therapy-and-immunotherapy
#13
REVIEW
Katharine Hall Thomas, Robert A Ramirez
Background: Leptomeningeal disease (LMD) is a complication that results from solid tumor metastasis. Prognosis is extremely poor. As therapeutic options for solid tumors improve, the rate of LMD continues to increase. Until recently, treatment has been limited to radiation therapy, intrathecal chemotherapy, and systemic chemotherapy, with an overall survival of 2-3 months. Targeted molecular therapy and immunotherapies are promising new options for increasing overall survival and clinical improvement; however, optimal clinical management remains unknown...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29229752/ribociclib-extends-survival-in-hr-breast-cancer
#14
(no author information available yet)
Adding the CDK4/6 inhibitor ribociclib to standard first-line endocrine therapy significantly prolonged survival in premenopausal and perimenopausal women with advanced HR-positive, HER2-negative breast cancer enrolled in the MONALEESA-7 trial. This is the first definitive evidence that CDK4/6 inhibitor-based therapy is effective for first-line treatment of premenopausal and perimenopausal women.
December 11, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29229318/low-dose-chemotherapy-combined-with-attenuated-salmonella-decreases-tumor-burden-and-is-less-toxic-than-high-dose-chemotherapy-in-an-autochthonous-murine-model-of-breast-cancer
#15
Daniel Saltzman, Lance Augustin, Arnold Leonard, Michael Mertensotto, Janet Schottel
BACKGROUND: Immunotherapies for cancer treatment have demonstrated substantial promise even though toxicities and development of tumor resistance limit their effectiveness. A combinatorial approach using immunotherapy with other treatment modalities may decrease side effects while maintaining maximal therapeutic effect. We aimed to determine if bacterial immunotherapy in combination with a chemotherapeutic would be efficacious and less toxic than conventional chemotherapy in an established, preclinical, autochthonous tumor model...
December 8, 2017: Surgery
https://www.readbyqxmd.com/read/29228676/genes-with-mutation-significance-were-highly-associated-with-the-clinical-pattern-of-patients-with-breast-cancer
#16
Wan-Jun Ding, Tao Zeng, Li-Jun Wang, Hong-Bo Lei, Wei Ge, Zhi Wang
In the United States, breast cancer is the second leading cause of cancer death in women. Over the past 20 years, breast cancer incidence and mortality rates increased rapidly in developing regions. We aimed to identify the gene mutation patterns that associated with the clinical patterns, including survival status, histo-pathological classes and so forth, of breast cancer. We retrieved 1098 cases of the clinical information, and level-3 legacy data of mRNA expression level, protein expression data and mutation files from GDC data portal...
November 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228411/management-of-breast-cancer-in-adjuvant-chemotherapy-settings-in-the-kanagawa-breast-oncology-group
#17
Mayako Terao, Naoki Niikura, Yasuhiro Suzuki, Norihiko Sengoku, Hitoshi Arioka, Takashi Ishikawa, Koichiro Tsugawa, Yutaka Tokuda
OBJECTIVE: Many different options for adjuvant chemotherapy are recommended in guidelines for the treatment of breast cancer. Therapeutic strategies vary among physicians. The major goals for this project were to gain a better understanding of how biomarkers are integrated into practice and how physicians select adjuvant chemotherapy. METHODS: We assembled a questionnaire with 23 example scenarios of breast cancer cases, including 6 items relevant to postoperative adjuvant therapy...
December 20, 2017: Tokai Journal of Experimental and Clinical Medicine
https://www.readbyqxmd.com/read/29228091/a-randomized-phase-ii-study-evaluating-different-maintenance-schedules-of-nab-paclitaxel-in-the-first-line-treatment-of-metastatic-breast-cancer-final-results-of-the-ibcsg-42-12-big-2-12-snap-trial
#18
A Gennari, Z Sun, U Hasler-Strub, M Colleoni, M J Kennedy, R Von Moos, J Cortés, M J Vidal, B Hennessy, J Walshe, K Amillano Parraga, K Ribi, J Bernhard, S Murillo Morales, O Pagani, A Barbeaux, S Borstnar, M Rabaglio-Poretti, R Maibach, M M Regan, G Jerusalem
Background: The phase II SNAP trial was designed to evaluate the efficacy of alternative chemotherapy schedules for prolonged administration in HER2-negative metastatic breast cancer (MBC), after a short induction at conventional doses. Methods: Between April 2013 and August 2015, 258 women untreated with chemotherapy for MBC were randomly assigned to receive three different maintenance chemotherapy schedules after three cycles of identical induction chemotherapy: Arm A, nab-Paclitaxel 150 mg/m2 days 1,15 Q28; Arm B, nab-Paclitaxel 100 mg/m2 days 1,8,15 Q28; Arm C, nab-Paclitaxel 75 mg/m2 days 1,8,15,22 Q28...
December 8, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29227816/the-use-of-breast-imaging-for-predicting-response-to%C3%A2-neoadjuvant-lapatinib-trastuzumab-and-their-combination-in-her2-positive-breast-cancer-results%C3%A2-from-neo-altto
#19
S Di Cosimo, C Campbell, H A Azim, G Galli, G Bregni, G Curigliano, C Criscitiello, M Izquierdo, L de la Pena, D Fumagalli, L Fein, J Vinholes, W M J Ng, M Colleoni, A Ferro, B J Naume, A Patel, J Huober, M J Piccart-Gebhart, J Baselga, E de Azambuja
AIM: To determine the value of mammography and breast ultrasound (US) in predicting outcomes in HER2 positive breast cancer patients (pts) within Neo-ALTTO trial. PATIENTS AND METHODS: Mammography and US were required at baseline, week 6 and surgery. Two independent blinded investigators reviewed the measurements and assigned the corresponding response category. Pts showing complete or partial response according to RECIST (v1.1) were classified as responders. The association between imaging response at week 6 or prior to surgery was evaluated with respect to pathological complete response (pCR) and event-free Survival (EFS)...
December 8, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/29225726/incidence-diagnosis-and-treatment-of-cardiac-toxicity-from-trastuzumab-in-patients-with-breast-cancer
#20
Somaira Nowsheen, Paul V Viscuse, Ciara C O'Sullivan, Nicole P Sandhu, Tufia C Haddad, Anne Blaes, Jennifer Klemp, Lara Nhola, Joerg Herrmann, Kathryn J Ruddy
Purpose of review: Treatment with trastuzumab is a cornerstone of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but carries an unfortunate risk of toxicity to the cardiovascular system. Here we review recent findings on trastuzumab-associated cardiotoxicity, focusing on its incidence, diagnosis, and treatment. Recent findings: Screening with multigated acquisition scan (MUGA) or echocardiogram (ECHO) is recommended to assess cardiac function prior to and during trastuzumab therapy...
September 2017: Current Breast Cancer Reports
keyword
keyword
5319
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"